Valneva To Highlight Lyme Disease Vaccine VLA15 And Commercial Portfolio At U.S. & European Investor Conferences In June 2025

Benzinga · 05/26 15:42

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025.

Key topics for discussion include Valneva's commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world's leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being evaluated in a pivotal Phase 3 trial for which the Company expects first data at the end of 2025.